Recent Quotes (30 days)

You have no recent quotes
chg | %

Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
0.00 (0.00%)
Dec 9 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 20.22 - 20.93
52 week 18.41 - 165.77
Open 20.39
Vol / Avg. 940,630.00/1.65M
Mkt cap 7.10B
P/E     -
Div/yield     -
EPS -8.55
Shares 341.19M
Beta -0.60
Inst. own 83%
Dec 14, 2016
Valeant Pharmaceuticals International Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference - 1:30PM EST - Add to calendar
Dec 13, 2016
Valeant Pharmaceuticals International Inc at Guggenheim Boston Healthcare Conference - 11:45AM EST - Add to calendar
Nov 15, 2016
Valeant Pharmaceuticals International Inc at Stifel Healthcare Conference - Webcast
Nov 8, 2016
Q3 2016 Valeant Pharmaceuticals International Inc Earnings Release
Nov 8, 2016
Q3 2016 Valeant Pharmaceuticals International Inc Earnings Call
Sep 13, 2016
Valeant Pharmaceuticals International Inc at Morgan Stanley Global Healthcare Conference - Webcast

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -49.17% -2.75%
Operating margin -34.80% 14.43%
EBITD margin - 45.71%
Return on average assets -10.47% -0.76%
Return on average equity -103.28% -5.21%
Employees 22,000 -
CDP Score - -


2150 Saint-Elzear Blvd W
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links


Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 60
Paul S. Herendeen Chief Financial Officer, Executive Vice President - Finance
Age: 60
Pavel Mirovsky President, General Manager, Europe
Age: 65
Christina Ackermann Executive Vice President, General Counsel
Thomas Appio Executive Vice President, President - Asia Pacific
Ari S. Kellen Executive Vice President, Company Group Chairman
Age: 52
Robert L. Rosiello Executive Vice President - Corporate Development and Strategy
Age: 58
Anne C. Whitaker Executive Vice President
Age: 49
Louis W. Yu Ph.D. Chief Quality Officer, Global Quality
Age: 65
Thomas W. Ross Sr. Lead Independent Director
Age: 65